Literature DB >> 15589713

Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence.

Angela J Dean1, James Bell, Macdonald J Christie, Richard P Mattick.   

Abstract

Research suggests that buprenorphine may possess antidepressant activity. The Beck Depression Inventory was completed at baseline and 3 months by heroin dependent subjects receiving either buprenorphine or methadone maintenance as part of a larger, pre-existing, double blind trial conducted by NDARC (Australia). Depressive symptoms improved in all subjects, with no difference between methadone and buprenorphine groups, suggesting no differential benefit on depressive symptoms for buprenorphine compared to methadone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15589713     DOI: 10.1016/j.eurpsy.2004.09.002

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  22 in total

1.  Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.

Authors:  Jonathan D Savant; Declan T Barry; Christopher J Cutter; Michelle T Joy; An Dinh; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2012-07-06       Impact factor: 4.492

2.  Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder.

Authors:  Zev Schuman-Olivier; M Claire Greene; Brandon G Bergman; John F Kelly
Journal:  Drug Alcohol Depend       Date:  2014-09-18       Impact factor: 4.492

3.  Opioidergic Agents as Antidepressants: Rationale and Promise.

Authors:  Parnika P Saxena; J Alexander Bodkin
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

4.  Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons.

Authors:  Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2010-07-03

Review 5.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

6.  Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.

Authors:  Kelly R Peck; Taylor A Ochalek; Gary J Badger; Stacey C Sigmon
Journal:  Drug Alcohol Depend       Date:  2020-01-22       Impact factor: 4.492

7.  The Role of Opiates in Social Pain and Suicidal Behavior.

Authors:  Benedicte Nobile; Pierre-Eric Lutz; Emilie Olie; Philippe Courtet
Journal:  Curr Top Behav Neurosci       Date:  2020

8.  Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.

Authors:  Andrew C Kruegel; Madalee M Gassaway; Abhijeet Kapoor; András Váradi; Susruta Majumdar; Marta Filizola; Jonathan A Javitch; Dalibor Sames
Journal:  J Am Chem Soc       Date:  2016-05-18       Impact factor: 15.419

9.  Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Authors:  Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

10.  Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.

Authors:  Angela J Dean; John B Saunders; Rod T Jones; Ross M Young; Jason P Connor; Bruce R Lawford
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.